U.S. Basic Materials Stock News

BankUnited, Inc. reported second-quarter 2026 results showing net interest income of US$255.33 million and net income of US$70.66 million, both modestly higher than a year earlier, with diluted EPS from continuing operations rising to US$0.97. Alongside this earnings improvement, the bank’s net charge-offs roughly halved to US$6.37 million and it completed a US$154.18 million buyback retiring 4.68% of its shares, underscoring management’s focus on credit quality and capital returns. We’ll...

Geopolitics, oil prices and interest rate expectations just collided in a way that puts US airlines and travel stocks back in focus. President Trump’s decision to cancel planned strikes on Iran eased conflict risks, helped pull oil sharply lower and coincided with a strong move in the Dow, S&P 500 and Nasdaq. That mix can quickly reshape expectations for fuel costs, demand and risk appetite. This article walks through 3 US airlines and travel stocks exposed to this news, explaining why some...

10x Genomics (TXG) stock is in focus after the company announced a multi year research collaboration with Lausanne University Hospital to study cancer diagnostics using its single cell and spatial platforms. See our latest analysis for 10x Genomics. The Lausanne collaboration lands at a moment when 10x Genomics has been in sharp focus, with the share price at US$47.27 and a 30 day share price return of 21.05% feeding into a 90 day share price return of 110.74% and a 1 year total shareholder...

In July 2026, First Merchants Corporation reported second-quarter and first-half results showing higher net interest income, with US$158.94 million for the quarter and US$310.24 million for the six months, compared with the prior year. Despite this revenue-related improvement, net income and earnings per share from continuing operations fell for both periods, highlighting pressure on overall profitability even as the bank’s core lending engine expanded. We’ll now examine how this mix of...

Over the last 7 days, the United States market has remained flat, yet it is up 18% over the past year with earnings projected to grow by 16% annually in the coming years. In this environment, identifying stocks that are trading below their fair value can present opportunities for investors looking to capitalize on potential growth while minimizing risk.

Over the last 7 days, the United States market has remained flat, yet it has experienced an impressive 18% rise over the past year, with earnings forecasted to grow by 16% annually. In such a climate, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.

The market remained flat over the last week, yet it is up 18% over the past year, with earnings forecast to grow by 16% annually. Investing in penny stocks—often smaller or newer companies—can still open doors to growth opportunities, particularly when these stocks are backed by strong financial health. This article explores several penny stocks that offer compelling opportunities with less risk than one might expect, showcasing above-average balance sheet resilience.

The United States market remained flat over the last week, but it has risen 18% over the past year with earnings forecasted to grow by 16% annually. In this environment, identifying strong dividend stocks can be an effective strategy for investors seeking stable income and potential capital appreciation.

With inflation still running above the Fed’s 2% target and rate expectations shifting with every new comment from policymakers, many investors are rethinking how to position their portfolios. Defensive sector stocks can sometimes offer a steadier ride when interest rates and bond yields are in focus, because these companies sell essential goods and services that people tend to keep buying. This article looks at three U.S. defensive stocks that are closely exposed to the latest Federal Reserve...

Biglari Holdings stock performance snapshot Biglari Holdings (BH.A) has drawn investor attention after recent share price moves, with the stock last closing at US$1,984.54. Returns show mixed short term performance, with a decline over the past month but gains over the past 3 months. See our latest analysis for Biglari Holdings. For context, Biglari Holdings has seen its share price pull back over the past month, even after a strong 3 month share price return of 28.42% and a 1 year total...

Bread Financial Holdings, Inc. reported second-quarter 2026 results with net interest income of US$1,039 million and net income of US$146 million, while also completing a buyback of 7,343,098 shares for US$551.36 million and declaring a quarterly dividend of US$0.23 per share payable on September 15, 2026. The combination of higher earnings per share, a large completed repurchase that reduced the share count, and continued cash returns through dividends underscores management’s ongoing focus...

The latest round of Section 301 and Section 338 tariffs is prompting investors to reconsider how exposed portfolios are to complex global supply chains. Higher duties, extra compliance checks and uncertain trade rules can all squeeze margins or re-route production closer to home. That is where a curated US manufacturing and onshoring screener can help focus attention. It filters for larger, financially healthy companies with operations rooted in North America. In this article, you will see...

TriMas Corporation’s recent second-quarter and six-month 2026 results showed slightly higher sales of US$174.58 million and US$342.86 million respectively, alongside lower quarterly net income of US$13.37 million but a very large six‑month net income of US$814.2 million, while continuing its share repurchase program and affirming a US$0.0400 quarterly dividend. Beneath the headline numbers, the combination of improved profitability from continuing operations, a long-running buyback that has...

Jackson Financial (JXN) is entering a planned leadership transition that will place longtime finance executive Don W. Cummings in the Chief Executive Officer role and elevate Brian M. Walta to Chief Financial Officer. See our latest analysis for Jackson Financial. Jackson Financial’s leadership reshuffle arrives during a period of strong stock momentum, with a 30 day share price return of 16.98%, year to date share price return of 13.79%, and a 1 year total shareholder return of 50.40%,...

Teleflex Incorporated recently received U.S. FDA Biologics License Application approval for EZPLAZ Freeze Dried Plasma, the first FDA-licensed freeze dried plasma for adult transfusions when conventional plasma products are unavailable. This approval gives Teleflex its first biologics license for a blood component and introduces a patented flexible bag format that addresses battlefield and prehospital trauma care logistics. We’ll now examine how this first-of-its-kind FDA-approved freeze...

Capitol Federal Financial, Inc. recently reported third-quarter 2026 results, including US$53.48 million in net interest income, US$23.57 million in net income, minimal net charge-offs of US$148,000, completion of a 9,976,478-share buyback totaling US$72.84 million, and reaffirmed a US$0.085 quarterly dividend per share. Together, higher net interest income, growing net income and the completed share repurchase program underscore management’s clear emphasis on capital return and operating...

MetroCity Bankshares earnings trigger fresh interest MetroCity Bankshares (MCBS) has drawn investor attention after reporting second quarter 2026 results, with net interest income of $44.04 million and net income of $22.13 million, both higher than the prior year period. See our latest analysis for MetroCity Bankshares. MetroCity Bankshares has seen mixed trading around the earnings release, with the share price slipping 4.09% over the past month but still posting a 34.68% year to date share...

Why First Busey’s latest earnings and buyback matter for investors First Busey (BUSE) has drawn fresh attention after second quarter and year to date results showed much higher net income and earnings per share, alongside the completion of a multi year share repurchase program. See our latest analysis for First Busey. At a share price of $30.86, First Busey has delivered a 15.97% 90 day share price return and a 45.10% 1 year total shareholder return, which indicates that recent earnings and...

Eton Pharmaceuticals (ETON) has filed a Prior Approval Supplement with the U.S. Food and Drug Administration to expand KHINDIVI’s label to younger pediatric patients, following bioequivalence data versus ALKINDI SPRINKLE hydrocortisone granules. See our latest analysis for Eton Pharmaceuticals. The KHINDIVI label expansion filing comes after a very strong run in Eton Pharmaceuticals’ stock, with a 30 day share price return of 26.73%, a 90 day share price return of 60.62% and a year to date...

In late July 2026, Myriad Genetics reported second-quarter results showing revenue of US$190.7 million versus US$213.1 million a year earlier, alongside a reduced full-year 2026 revenue outlook of US$770 million to US$790 million due to weaker Prenatal Health test volumes and more cautious assumptions for revenue per test. Despite the revenue decline, the company’s net loss narrowed sharply to US$43.2 million from a very large loss a year ago, highlighting significant cost or non-operational...

Q2 results and capital return actions in focus for Hyatt Hotels stock Hyatt Hotels (H) has drawn investor attention after its second quarter 2026 earnings, the Board-approved third quarter dividend, an updated full-year net income outlook, and progress on a multi-year share repurchase program. See our latest analysis for Hyatt Hotels. Despite Q2 earnings, guidance and capital returns in focus, Hyatt Hotels shares have pulled back recently, with the 30 day share price return down 8.8% and the...

In late July 2026, Core Scientific, Inc. reported Q2 2026 revenue of US$164.2 million alongside a net loss of US$1.16 billion, and announced a large‑scale AI infrastructure partnership with Advanced Micro Devices, Inc. involving up to 2.5 gigawatts of potential data center capacity and related stock warrants for Advanced Micro Devices, Inc. Core Scientific, Inc. also added veteran technology executive Mark W. Adams to its expanded seven‑member Board of Directors, strengthening oversight as...

Tariffs on Canadian imports and higher taxes on generic drugs are shaking up expectations for costs and pricing across healthcare. For U.S. specialty pharmaceutical manufacturers, this mix of pressure and opportunity can be important. Some companies may face higher input costs. Others with more domestic production may see a relative edge if imported generics become more expensive. This article explains how the new trade measures could matter for your portfolio and discusses 3 U.S. specialty...

Last week saw the newest quarterly earnings release from BigBear.ai Holdings, Inc. ( NYSE:BBAI ), an important...